免疫检查点阻断：癌症治疗的一种通用方法。
Immune checkpoint blockade: a common denominator approach to cancer therapy.
作者信息
Topalian Suzanne L, Drake Charles G, Pardoll Drew M
机构信息
Department of Surgery, Sidney Kimmel Comprehensive Cancer Center and Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
The Brady Urological Institute, Sidney Kimmel Comprehensive Cancer Center and Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center and Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
出版信息
Cancer Cell. 2015 Apr 13;27(4):450-61. doi: 10.1016/j.ccell.2015.03.001. Epub 2015 Apr 6.
Abstract
The immune system recognizes and is poised to eliminate cancer but is held in check by inhibitory receptors and ligands. These immune checkpoint pathways, which normally maintain self-tolerance and limit collateral tissue damage during anti-microbial immune responses, can be co-opted by cancer to evade immune destruction. Drugs interrupting immune checkpoints, such as anti-CTLA-4, anti-PD-1, anti-PD-L1, and others in early development, can unleash anti-tumor immunity and mediate durable cancer regressions. The complex biology of immune checkpoint pathways still contains many mysteries, and the full activity spectrum of checkpoint-blocking drugs, used alone or in combination, is currently the subject of intense study.
摘要
免疫系统能够识别并准备好清除癌症，但却受到抑制性受体和配体的制约。这些免疫检查点通路通常在抗微生物免疫反应期间维持自身耐受性并限制附带的组织损伤，癌症却可利用它们来逃避免疫破坏。阻断免疫检查点的药物，如抗CTLA-4、抗PD-1、抗PD-L1以及其他处于早期研发阶段的药物，能够释放抗肿瘤免疫力并介导持久的癌症消退。免疫检查点通路的复杂生物学特性仍存在许多谜团，目前，单独或联合使用检查点阻断药物的全部活性谱是深入研究的主题。
相似文献
1
Immune checkpoint blockade: a common denominator approach to cancer therapy.免疫检查点阻断：癌症治疗的一种通用方法。
Cancer Cell. 2015 Apr 13;27(4):450-61. doi: 10.1016/j.ccell.2015.03.001. Epub 2015 Apr 6.
2
Immune Checkpoint Blockade in Cancer Therapy.癌症治疗中的免疫检查点阻断疗法
J Clin Oncol. 2015 Jun 10;33(17):1974-82. doi: 10.1200/JCO.2014.59.4358. Epub 2015 Jan 20.
3
A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.免疫疗法在泌尿系统肿瘤中的系统评价：CTLA-4、PD-1/PD-L1 和 HLA-G 靶向作用的不断演变。
Eur Urol. 2015 Aug;68(2):267-79. doi: 10.1016/j.eururo.2015.02.032. Epub 2015 Mar 29.
4
Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.乳腺癌治疗的免疫疗法：检查点阻断、癌症疫苗及联合免疫疗法的未来方向
Clin Adv Hematol Oncol. 2016 Nov;14(11):922-933.
5
PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?单独使用PD-1检查点阻断疗法或联合使用PD-1和CTLA-4阻断疗法作为肺癌的免疫疗法？
Expert Opin Biol Ther. 2017 Mar;17(3):305-312. doi: 10.1080/14712598.2017.1280454. Epub 2017 Jan 18.
6
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.CTLA-4 和 PD-1/PD-L1 阻断：黑色素瘤患者具有持久临床获益的新免疫治疗方式。
Clin Cancer Res. 2013 Oct 1;19(19):5300-9. doi: 10.1158/1078-0432.CCR-13-0143.
7
Immune Checkpoint Blockade in Breast Cancer Therapy.免疫检查点阻断在乳腺癌治疗中的应用。
Adv Exp Med Biol. 2017;1026:383-402. doi: 10.1007/978-981-10-6020-5_18.
8
The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.PD-1和CTLA-4之后免疫检查点癌症治疗的未来。
Immunotherapy. 2017 Jun;9(8):681-692. doi: 10.2217/imt-2017-0024.
9
Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.针对免疫检查点受体和分子的自然杀伤细胞治疗调节。
Front Immunol. 2018 Sep 10;9:2041. doi: 10.3389/fimmu.2018.02041. eCollection 2018.
10
Coinhibitory Pathways in Immunotherapy for Cancer.癌症免疫治疗中的共抑制途径。
Annu Rev Immunol. 2016 May 20;34:539-73. doi: 10.1146/annurev-immunol-032414-112049. Epub 2016 Feb 25.
引用本文的文献
1
Comprehensive pan-cancer analysis reveals ubiquitin-conjugating enzyme 2T as a potential biomarker for prognosis and cancer immunity.全面的泛癌分析揭示泛素结合酶2T作为一种潜在的预后和癌症免疫生物标志物。
Oncol Lett. 2025 Aug 20;30(5):491. doi: 10.3892/ol.2025.15237. eCollection 2025 Nov.
2
Dual molecularly imprinted nanocomposite with transferrin mediated glioma targeting and cholesterol exhaustion for synergistic cuproptosis/immune checkpoint blockade/immunogenic cell death.具有转铁蛋白介导的胶质瘤靶向和胆固醇耗竭功能的双分子印迹纳米复合材料，用于协同铜死亡/免疫检查点阻断/免疫原性细胞死亡。
Mater Today Bio. 2025 Aug 16;34:102209. doi: 10.1016/j.mtbio.2025.102209. eCollection 2025 Oct.
3
Integrated pan-cancer and melanoma-specific analysis of angiopoietin-2: prognostic value, immune microenvironment modulation, and ceRNA network regulation.血管生成素-2的泛癌和黑色素瘤特异性综合分析：预后价值、免疫微环境调节及ceRNA网络调控
Discov Oncol. 2025 Sep 1;16(1):1666. doi: 10.1007/s12672-025-03448-5.
4
Preexisting ulcerative colitis increases the risk of immune-related colitis and predicts divergent survival outcomes in gastrointestinal cancer patients treated with immune checkpoint inhibitors.既往存在的溃疡性结肠炎会增加免疫相关性结肠炎的风险，并预示接受免疫检查点抑制剂治疗的胃肠道癌症患者有不同的生存结局。
Front Immunol. 2025 Aug 13;16:1627680. doi: 10.3389/fimmu.2025.1627680. eCollection 2025.
5
Combination Strategies with HSP90 Inhibitors in Cancer Therapy: Mechanisms, Challenges, and Future Perspectives.癌症治疗中HSP90抑制剂的联合策略：作用机制、挑战与未来展望
Pharmaceuticals (Basel). 2025 Jul 22;18(8):1083. doi: 10.3390/ph18081083.
6
CD20-Negative Large B-Cell Lymphomas: The Diagnostic Challenge of Tumors with Downregulation of Mature B-Cell Marker Expression.CD20阴性大B细胞淋巴瘤：成熟B细胞标志物表达下调肿瘤的诊断挑战
Int J Mol Sci. 2025 Aug 14;26(16):7843. doi: 10.3390/ijms26167843.
7
Low Antibody Dosing in Cancer Therapy: Targeted Cytotoxicity Combined with Anti-Tumour Immunostimulation.癌症治疗中的低抗体剂量：靶向细胞毒性与抗肿瘤免疫刺激相结合
Int J Mol Sci. 2025 Aug 10;26(16):7724. doi: 10.3390/ijms26167724.
8
Tumor-intrinsic interferon signaling drives pancreatic cancer resistance to tumor mucin1-targeted CAR T cell therapy.肿瘤内在的干扰素信号传导驱动胰腺癌对靶向肿瘤黏蛋白1的嵌合抗原受体T细胞疗法产生抗性。
Front Immunol. 2025 Aug 8;16:1618415. doi: 10.3389/fimmu.2025.1618415. eCollection 2025.
9
Nanoengineered-based delivery systems to modulate CD4 T cell responses in cancer: emerging paradigms in cancer immunotherapy.基于纳米工程的递送系统调节癌症中CD4 T细胞反应：癌症免疫治疗的新兴范例
Front Pharmacol. 2025 Aug 11;16:1643791. doi: 10.3389/fphar.2025.1643791. eCollection 2025.
10
A novel immune-metabolic prognostic model stratifies survival and personalizes therapy in hepatocellular carcinoma.一种新型免疫代谢预后模型可对肝细胞癌患者的生存情况进行分层并实现个体化治疗。
Discov Oncol. 2025 Aug 24;16(1):1607. doi: 10.1007/s12672-025-03281-w.
本文引用的文献
1
Antagonists of PD-1 and PD-L1 in Cancer Treatment.癌症治疗中PD-1和PD-L1的拮抗剂。
Semin Oncol. 2015 Aug;42(4):587-600. doi: 10.1053/j.seminoncol.2015.05.013. Epub 2015 Jun 10.
2
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.接受纳武利尤单抗治疗的既往治疗过的晚期肾细胞癌患者的生存、持久缓解及长期安全性
J Clin Oncol. 2015 Jun 20;33(18):2013-20. doi: 10.1200/JCO.2014.58.1041. Epub 2015 Mar 30.
3
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.伊匹单抗治疗不可切除或转移性黑色素瘤的II期和III期试验长期生存数据的汇总分析
J Clin Oncol. 2015 Jun 10;33(17):1889-94. doi: 10.1200/JCO.2014.56.2736. Epub 2015 Feb 9.
4
Balance and imbalance in the immune system: life on the edge.免疫系统中的平衡与失衡：边缘生活
Immunity. 2014 Nov 20;41(5):682-4. doi: 10.1016/j.immuni.2014.11.005.
5
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.纳武利尤单抗治疗复发或难治性霍奇金淋巴瘤的 PD-1 阻断作用。
N Engl J Med. 2015 Jan 22;372(4):311-9. doi: 10.1056/NEJMoa1411087. Epub 2014 Dec 6.
6
The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.免疫受体 TIGIT 调节抗肿瘤和抗病毒 CD8(+) T 细胞效应功能。
Cancer Cell. 2014 Dec 8;26(6):923-937. doi: 10.1016/j.ccell.2014.10.018. Epub 2014 Nov 26.
7
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.纳武单抗治疗转移性肾细胞癌：一项随机II期试验的结果
J Clin Oncol. 2015 May 1;33(13):1430-7. doi: 10.1200/JCO.2014.59.0703. Epub 2014 Dec 1.
8
Current perspectives on immunotherapy.免疫疗法的当前观点。
Semin Oncol. 2014 Oct;41 Suppl 5:S14-29. doi: 10.1053/j.seminoncol.2014.09.003. Epub 2014 Sep 8.
9
PD-1 blockade induces responses by inhibiting adaptive immune resistance.程序性死亡受体1（PD-1）阻断通过抑制适应性免疫抵抗来诱导反应。
Nature. 2014 Nov 27;515(7528):568-71. doi: 10.1038/nature13954.
10
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.癌症患者对抗PD-L1抗体MPDL3280A反应的预测性相关因素。
Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011.
Zotero 插件